Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Peter Iversen; David G McLeod; William A See; Thomas Morris; Jon Armstrong; Manfred P Wirth; Casodex Early Prostate Cancer Trialists' Group

doi:10.1111/j.1464-410X.2010.09319.x

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Peter Iversen
, David G McLeod
, William A See
, Thomas Morris
, Jon Armstrong
, Manfred P Wirth
, Casodex Early Prostate Cancer Trialists' Group

98 Citationer (Scopus)

Abstract

To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

Originalsprog	Engelsk
Tidsskrift	BJU International
Vol/bind	105
Udgave nummer	8
Sider (fra-til)	1074-81
Antal sider	8
ISSN	1464-4096
DOI	https://doi.org/10.1111/j.1464-410X.2010.09319.x
Status	Udgivet - 2010

Adgang til dokumentet

10.1111/j.1464-410X.2010.09319.x

Citationsformater

Iversen, P., McLeod, D. G., See, W. A., Morris, T., Armstrong, J., Wirth, M. P., & Casodex Early Prostate Cancer Trialists' Group (2010). Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU International, 105(8), 1074-81. https://doi.org/10.1111/j.1464-410X.2010.09319.x

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. / Iversen, Peter; McLeod, David G; See, William A et al.
I: BJU International, Bind 105, Nr. 8, 2010, s. 1074-81.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Iversen, P, McLeod, DG, See, WA, Morris, T, Armstrong, J, Wirth, MP & Casodex Early Prostate Cancer Trialists' Group 2010, 'Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years', BJU International, bind 105, nr. 8, s. 1074-81. https://doi.org/10.1111/j.1464-410X.2010.09319.x

@article{446cff0617224e8eb7359056990d8064,

title = "Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years",

abstract = "To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.",

keywords = "Adult, Aged, Androgen Antagonists, Anilides, Antineoplastic Agents, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nitriles, Prostatic Neoplasms, Tosyl Compounds",

author = "Peter Iversen and McLeod, \{David G\} and See, \{William A\} and Thomas Morris and Jon Armstrong and Wirth, \{Manfred P\} and \{Casodex Early Prostate Cancer Trialists' Group\}",

note = "[PETER IVERSEN], [MANFRED P. WIRTH], ASTRAZENECA, [US FEDERAL GOVERNMENT] 2010. JOURNAL COMPILATION {\textcopyright} 2010 BJU INTERNATIONAL.",

year = "2010",

doi = "10.1111/j.1464-410X.2010.09319.x",

language = "English",

volume = "105",

pages = "1074--81",

journal = "BJU International",

issn = "1464-4096",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer

T2 - final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

AU - Iversen, Peter

AU - McLeod, David G

AU - See, William A

AU - Morris, Thomas

AU - Armstrong, Jon

AU - Wirth, Manfred P

AU - Casodex Early Prostate Cancer Trialists' Group

PY - 2010

Y1 - 2010

N2 - To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

AB - To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

KW - Adult

KW - Aged

KW - Androgen Antagonists

KW - Anilides

KW - Antineoplastic Agents

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Follow-Up Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Nitriles

KW - Prostatic Neoplasms

KW - Tosyl Compounds

U2 - 10.1111/j.1464-410X.2010.09319.x

DO - 10.1111/j.1464-410X.2010.09319.x

M3 - Journal article

C2 - 22129214

SN - 1464-4096

VL - 105

SP - 1074

EP - 1081

JO - BJU International

JF - BJU International

IS - 8

ER -

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater